ABL2

Across TCGA pan-cancer cohorts, ABL2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of ABL2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ABL2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ABL2 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

HNSC, KIRC, and KIRP are the cancer types where ABL2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ABL2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	IV	+2.083	<.001	12	view →
KIRC	Female	All	+0.996	<.001	11	view →
KIRP	All	II,III,IV	+0.826	<.001	11	view →
LIHC	Male	II,III,IV	+1.175	<.001	9	view →
COAD	All	II,III,IV	+0.460	<.001	7	view →
READ	All	III,IV	+1.299	.001	6	view →
STAD	Male	II,III,IV	+1.190	<.001	6	view →
LUAD	All	II,III,IV	+0.569	<.001	6	view →
BRCA	All	II,III,IV	+0.519	<.001	6	view →
CHOL	Male	All	+2.618	<.001	3	view →
KICH	Female	All	−0.971	.001	3	view →
ESCA	All	All	+0.762	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

ABL2–HNSC

Open the HNSC breakdown →